Gene · 8438
Papers1,865
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 1,865
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Dysregulation of Non-Coding RNAs: Roles of miRNAs and lncRNAs in the Pathogenesis of Multiple Myeloma. | Noncoding RNA | 2023 | 37987364 | PubTator, text mining | PubMed |
| The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response. | Cancer Med | 2023 | 37986697 | PubTator, text mining | PubMed |
| Big data analysis identified a telomere-related signature predicting the prognosis and drug sensitivity in lung adenocarcinoma. | Medicine (Baltimore) | 2023 | 37986388 | PubTator, text mining | PubMed |
| H3.1K27me1 loss confers Arabidopsis resistance to Geminivirus by sequestering DNA repair proteins onto host genome. | Nat Commun | 2023 | 37980416 | PubTator, text mining | PubMed |
| Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51. | Nat Commun | 2023 | 37973845 | PubTator, text mining | PubMed |
| Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta? | Transl Cancer Res | 2023 | 37969378 | PubTator, text mining | PubMed |
| Organ-Specificity of Breast Cancer Metastasis. | Int J Mol Sci | 2023 | 37958607 | PubTator, text mining | PubMed |
| Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study. | Cancers (Basel) | 2023 | 37958398 | PubTator, text mining | PubMed |
| The Clinical Impact of Death Domain-Associated Protein and Holliday Junction Recognition Protein Expression in Cancer: Unmasking the Driving Forces of Neoplasia. | Cancers (Basel) | 2023 | 37958340 | PubTator, text mining | PubMed |
| A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis. | Diagnostics (Basel) | 2023 | 37958189 | PubTator, text mining | PubMed |
| PARP inhibitors combined with radiotherapy: are we ready? | Front Pharmacol | 2023 | 37954854 | PubTator, text mining | PubMed |
| Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial. | Oncogene | 2023 | 37945748 | PubTator, text mining | PubMed |
| Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. | Lancet Oncol | 2023 | 37922930 | PubTator, text mining | PubMed |
| Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study. | ESMO Open | 2023 | 37922692 | PubTator, text mining | PubMed |
| Global research trends of infantile hemangioma: A bibliometric and visualization analysis from 2000 to 2022. | Heliyon | 2023 | 37920523 | PubTator, text mining | PubMed |
| Structural basis for stabilisation of the RAD51 nucleoprotein filament by BRCA2. | Nat Commun | 2023 | 37919288 | PubTator, text mining | PubMed |
| Clinicopathological and molecular analysis of microsatellite instability in prostate cancer: a multi-institutional study in China. | Front Oncol | 2023 | 37901334 | PubTator, text mining | PubMed |
| DNA Double-Strand Break Response and Repair Gene Polymorphisms May Influence Therapy Results and Prognosis in Head and Neck Cancer Patients. | Cancers (Basel) | 2023 | 37894339 | PubTator, text mining | PubMed |
| De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment? | Cancers (Basel) | 2023 | 37894312 | PubTator, text mining | PubMed |
| FIGNL1 AAA+ ATPase remodels RAD51 and DMC1 filaments in pre-meiotic DNA replication and meiotic recombination. | Nat Commun | 2023 | 37891173 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8438/papers?page=7